Acoramidis (Attruby) gained FDA approval for treating wild-type or variant transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM), BridgeBio Pharma announced. Offering patients near-complete TTR ...
Acoramidis showed a 42% reduction in all-cause mortality and cardiovascular hospitalizations at 30 months compared to placebo in the ATTRibute-CM trial. Continuous acoramidis use resulted in a 48.2% ...
Acoramidis is the first FDA-approved treatment for ATTR-CM with near-complete TTR stabilization, reducing cardiovascular death and hospitalization. The phase 3 ATTRibute-CM trial showed acoramidis ...
BridgeBio Pharma, Inc. (NASDAQ: BBIO) on Sunday presented data from the ATTRibute-CM study. The study showed that acoramidis reduced cumulative cardiovascular outcomes, including cardiovascular ...
Please provide your email address to receive an email when new articles are posted on . Acoramidis reduced cumulative CV outcomes vs. placebo in patients with cardiac amyloidosis. The curves separated ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p<0.0001) and 49.3% in CVM (p<0.0001) -Acoramidis mitigated the rise in NT-proBNP through Month ...
A PDUFA target date of November 29, 2024 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for acoramidis for the treatment of ...
Please provide your email address to receive an email when new articles are posted on . In the 12-month topline results of the ATTRibute-CM trial, acoramidis, a treatment for symptomatic transthyretin ...
At first glance, Palo Alto, California based biotech / drug developer BridgeBio (BBIO) Pharma may not seem like the most attractive of investment opportunities. At the time of writing the company has ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results